Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Celularity (CELU) Change in Accured Expenses (2020 - 2025)

Celularity (CELU) has disclosed Change in Accured Expenses for 6 consecutive years, with $822000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Change in Accured Expenses fell 79.84% to $822000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $15.2 million, a 231.16% increase, with the full-year FY2024 number at $12.6 million, up 1220.04% from a year prior.
  • Change in Accured Expenses was $822000.0 for Q3 2025 at Celularity, down from $6.2 million in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $6.2 million in Q2 2025 to a low of -$9.2 million in Q4 2022.
  • A 5-year average of $886263.2 and a median of $888000.0 in 2023 define the central range for Change in Accured Expenses.
  • Biggest YoY gain for Change in Accured Expenses was 13765.96% in 2021; the steepest drop was 785.75% in 2021.
  • Celularity's Change in Accured Expenses stood at -$5.6 million in 2021, then tumbled by 62.37% to -$9.2 million in 2022, then skyrocketed by 70.98% to -$2.7 million in 2023, then soared by 302.82% to $5.4 million in 2024, then tumbled by 84.77% to $822000.0 in 2025.
  • Per Business Quant, the three most recent readings for CELU's Change in Accured Expenses are $822000.0 (Q3 2025), $6.2 million (Q2 2025), and $2.7 million (Q1 2025).